Randomized trial of daily high-dose vitamin D ₃ in patients with RRMS receiving subcutaneous interferon β-1a

Abstract

This study provides Class II evidence that for patients with RRMS treated with SC IFN-β-1a, 48 weeks of cholecalciferol supplementation did not promote NEDA-3 status.